Oncoinvent is a small life sciences company, delivering innovative cancer treatment by injecting radiopharmaceuticals directly into affected areas. This technology has the potential to allow more targeted treatment to regions of organs and the body which are difficult to access, while minimising harmful radiation doses. Oncoinvent’s products deliver treatment using radiopharmaceuticals incorporating the alpha-particle emitting radium-224 (Ra-224). The challenge with this approach is to quantify the amount of radioactivity administered to the patient and ultimately understand the dose delivered to the tumour.
Oncoinvent are developing Radspherin®, an inorganic microsphere containing Ra-224 which has been shown to cause a reduction in tumour cell growth in animal models and significantly increase survival rates. It has the potential to treat several forms of metastatic cancer.
The complexity of the decay chain and ingrowth equilibrium of Ra-224, and the decayed radioactive species, means significant expertise is required to develop primary and secondary standards and enable
in-situ measurement traceability. It is vital that accurate radioanalytical procedures are in place for the quality assurance checks of the product which will enable preclinical and clinical trials.
In addition, the microparticle delivery system for Ra-224 requires morphological and chemical characterisation to assess their stability during sterilisation, shipping, batch consistency and
absence of contaminants.